Wu, L., Wang, J., Li, Q., Wang, D., Zhang, C., Tang, J., Zhang, G., Hao, M., Yao, D., Gao, Q., Zhang, Y., An, R., Yin, R., Wang, L., Xia, B., Zhou, Q., Yang, H., Zhu, J., Jiang, K., Chen, Z., Wu, Q., Duan, W., Huang, Y., Zhang, H., Wei, S., Li, G., Meng, Y., Wang, K., Yang, X., Huang, X., Pan, L., Yu, J., Lou, G., Zhang, Y., Zhou, H., Guo, X., Yang, H., Cheng, X., Li, X., Wang, W., Zhao, H., Li, Y., Yang, Y., Lin, A., Cheng, W., Chen, L., Xie, X., Di, W., Hu, Y., Chen, M., Wen, H., Cai, L., Wu, X., Lin, Z., Wang, Q. (2026). Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS‐1): A multicenter, randomized, double‐blind, placebo‐controlled phase 3 trial. CA: A Cancer Journal for Clinicians. https://doi.org/10.3322/caac.70042